Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2010
03/10/2010CN100593402C 'Xindakang' dispersion tablets and preparation method
03/10/2010CN100593401C Combination of an aromatase inhibitor with a bisphosphonate
03/10/2010CN100593400C White hellebore alcohol and red phenolic acid B compound recipe preparation and its application
03/09/2010US7676269 Treatment of female fertility conditions through modulation of the autonomic nervous system
03/09/2010US7674938 Selective beta 3-adrenoceptor stimulants; obesity, diabetes mellitus, hyperlipidemia, pollakiuria, urinary incontinence, intestinal hypermotility; e.g. 4'-{2-[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methyl ethylamino]ethoxy}-2,3',5'-trimethylbiphenyl-4-carboxylic acid
03/09/2010US7674935 Crystal forms of O-desmethylvenlafaxine
03/09/2010US7674921 cloprostenol or latanoprost; topical use; highly crystalline structures that are easy to formulate into ophthalmic solutions; hydrolysis of these analogs releases only the active PGF2 alpha analog free acid, without the production of toxic and irritant small aliphatic alcohol coproducts
03/09/2010US7674913 Heterocyclic boronic acid compounds
03/09/2010US7674912 Phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl}ester; Parkinson's Disease; pro-drugs of A2A-receptor ligands with improved aqueous solubility
03/09/2010US7674909 Tetrahydroquinoline derivatives and their use as FSH receptor modulators
03/09/2010US7674908 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)-ethyl]8-azabicyclo[3.2.1]oct-3-yl}amide; improved pharmacokinetic, bioavailability; gastrointestinal disorders: irritable bowel syndrome (IBS), chronic constipation, dyspepsia; CNS behavioral, mood disorder
03/09/2010US7674907 2,3-diphenyl-N-((2S)-tetrahydro-2-furanylmethyl)furo[2,3-b]pyridin-4-amine; arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis
03/09/2010US7674906 4-[4-(4-Amino-phenyl)-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl]-benzoic acid methyl ester; rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis; CD80 antagonists capable of inhibiting the interactions between CD80 and CD28
03/09/2010US7674898 Anhydrous crystal of β-lactam compound and method for preparation thereof
03/09/2010US7674896 Short interference RNA duplexes when introduced into mammalian cells in culture perform sequence-specific inhibition of target mRNA without inducing an interferon response; for gene silencing to treat human diseases; double stranded siRNA
03/09/2010US7674895 Compositions and methods for siRNA inhibition of angiogenesis
03/09/2010US7674887 3'-{N'-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; thrombocytopenia and megakaryocytopoiesis treatment
03/09/2010US7674875 Star polymer such as of a polylactone based on a central phosphorus atom derived from phosphorus oxychloride (POCl3) or ethyl dichlorophosphate; biodegradable and/or biocompatible; sustained release drug delivery; reverse thermal gelation
03/09/2010US7674831 Heterocyclic compounds as sweetener enhancers
03/09/2010US7674830 Reducing blood glucose concentrations, weight loss, and treating diseases and conditions mediated by the cyclooxygenase-2 and 5-lipoxygenase enzymes; an enzyme inhibitors
03/09/2010US7674829 (S) 2-N (3-O-polypropyleneglycol) propylbenzene)-3-(4-hydroxyphenyl)propylamide; (S) 2-N (3-O-(polypropyleneglycol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide; inhibit cell growth whilst being of low toxicity to such cells
03/09/2010US7674828 Urea antagonists of P2Y1receptor useful in the treatment of thrombotic conditions
03/09/2010US7674826 adding benzoic acid to increase bone resistance and mineralization
03/09/2010US7674825 Cardiovascular disorders; stimulant of guanylate cyclase
03/09/2010US7674824 Stable oxaliplatin formulation
03/09/2010US7674823 DNA-PK inhibitors
03/09/2010US7674822 PTP1b inhibitors
03/09/2010US7674821 N-[[4-(4-bromophenyl)-5-(2,4-dichlorophenyl)-3-methyl-2-thienyl]methyl]-2-ethylbutanamide; cannabinoid CB1 receptor antagonists
03/09/2010US7674820 Ion channel modulating activity I
03/09/2010US7674819 4-(2-Cyano-cyclohexyloxy)-2-trifluoromethyl-benzonitrlle; selective androgen receptor modulators; decrease excess sebum secretions; stimulants of hair growth at higher rates of cosmetically acceptable hair growth in patients with alopecia; acne; skin disorders; prostate cancer
03/09/2010US7674818 Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
03/09/2010US7674816 N-(2-(5-methoxy-2-methoxyphenyl-1H-indol-3-yl)ethyl)acetamide; induce general anesthesia, sedation, and/or hypnotic or sleep effects; side effects reduction
03/09/2010US7674815 5-chloro-1H-indole-7-carboxylic acid benzofuran-2-ylmethyl-[2-(3,4-dichloro-phenyl)-ethyl]-amide; modulates plasma lipid levels; anticholesterol agents
03/09/2010US7674814 Angiotensin converting enzyme inhibitors; preparation of (2S,3aS,7aS)-1-((2S)-2-(((1S)-1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-1H-indol-2-carboxylic acid; hydrolysis; perindopril erbumine
03/09/2010US7674813 Lowering beta amyloid; Alzheimer's disease; gamma secretase inhibitors; pyrazole, imidazole, pyrrole and 1,2,4-triazole sulfonamides; e.g. 5-Chloro-N-{2-ethyl-1-[1-(4-methoxybenzyl)-1H-pyrazol-5-yl]butyl}thiophene-2-sulfonamide
03/09/2010US7674812 alpha-bisabolol; allantoin; aloe vera gel; acne, rosacea, atopic dermatitis, various seborrheas, eczema, psoriasis, various mite infestations, various scabies infestations, other inflammatory skin conditions
03/09/2010US7674811 5-lipoxygenase inhibitors
03/09/2010US7674809 Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production
03/09/2010US7674808 Heterocyclic compounds
03/09/2010US7674807 N-(1,1-dimethyl-2-methylsulfanyl-ethyl)-3-methanesulfonyloxy-phthalamic acid; 3-fluoro-N-(1-methyl-2-methylsulfanyl-ethyl)-phthalamic acid; effect against harmful insects without giving phytotoxicity on cultured plants
03/09/2010US7674806 Amidines and derivatives thereof and pharmaceutical compositions containing them
03/09/2010US7674805 Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics
03/09/2010US7674804 [1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(2-chloro-pyrimidin-4-yl)-amine; somatostatin receptor subtype 5 (SSTR5) antagonists; diabetes mellitus
03/09/2010US7674803 Thiazolypiperidine derivatives as MTP inhibitors
03/09/2010US7674802 leukotriene A4 hydrolase inhibitors; biaryl nitrogen-attached heterocycles
03/09/2010US7674800 Process of salt formation and by-product inhibition; FDA Orange Book listed patent for tradename Oxycontin
03/09/2010US7674799 Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
03/09/2010US7674798 Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
03/09/2010US7674797 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders
03/09/2010US7674796 Inhibitors of the FAK (focal adhesion kinase) protein tyrosine kinases, antiproliferative, antitumor; for example 5-{4-[(1-Hydroxy-cyclopentylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one
03/09/2010US7674795 Fluorene derivatives, composition containing said derivatives and the use thereof
03/09/2010US7674794 Fused bicycloheterocycle substituted quinuclidine derivatives
03/09/2010US7674793 Tricyclic dihydropyrazines as potassium channel openers
03/09/2010US7674792 for treatment of deficiencies in hematopoietic cells
03/09/2010US7674791 Triazolopyrazines and methods of making and using the same
03/09/2010US7674790 Processes of making and using pharmaceutical formulations of antineoplastic agents
03/09/2010US7674789 Compounds
03/09/2010US7674788 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors
03/09/2010US7674787 Conformationally constrained Smac mimetics and the uses thereof
03/09/2010US7674786 4-phenyl-N-substituted azetidin-2-ones; selective prostaglandin EP2 agonists; glaucoma or ocular hypertension
03/09/2010US7674784 Drug and food or drink for improving hyperglycemia
03/09/2010US7674783 Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
03/09/2010US7674782 One-step reaction with a water based solvent; reacting glycero-3-phosphorylcholine with either a permanganate or a mixture of periodic acid or salt and a di- or trivalent ruthenium compound; use as a surface treatment agent for e.g. plastics, metal, and glass to improve biocompatibility, hydrophilicity
03/09/2010US7674781 Hyaluronic acid-retaining polymers
03/09/2010US7674780 Iron sucrose complexes and method of manufacture thereof
03/09/2010US7674779 chemically modified oligonucleotides; double stranded iRNA agent; comprising a cholesterol moiety; increased stability in a biological sample
03/09/2010US7674778 Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
03/09/2010US7674777 Immunostimulatory nucleic acid molecules
03/09/2010US7674776 an anticonvulsant agent such as topiramate and a sympathomimetic agent such as phentermine; syndrome X; dosage forms
03/09/2010US7674775 4-(N (S-glutathionylacetyl)amino)phenylarsenoxide (GSAO) and derivatives; antiinflammatory and antitumor agents; blood and autoimmune disorders; viral infections; anticoagulants
03/09/2010US7674774 Abuse-resistant amphetamine prodrugs
03/09/2010US7674773 Glycosylated derivative of hypolipemic agents; side effect reduction; therapy for insulin resistance; hyperlipidemia agent; impaired lipid metabolism; lowering cholesterol levels
03/09/2010US7674769 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI)
03/09/2010US7674767 comprising 0.1-30 weight % complex of water-soluble drug and counter-ion substance in which charged water-soluble drug is bonded with counter-ion substance, 0.5-80 weight % lipid, 0.5-80 weight % polymer, and 1-80 weight % emulsifier; high gastrointestinal absorption rate; high drug entrapping rate
03/09/2010US7674750 comprising picolinafen or one of its environmentally compatible salts and a synergistically effective amount of a triazolopyrimidine herbicide selected from the triazolopyrimidine sulfonanilides and penoxsulam or salt thereof, and a safener
03/09/2010US7674617 MiRNA molecules isolated from human embryonic stem cell
03/09/2010US7674604 Using computer modeling to identify positions where cysteinal insertion will lock protein comprising integrin domain sequences into preferential configuration; directed protein evolution
03/09/2010US7674592 Methods for testing for the development of Huntington's disease
03/09/2010US7674490 Food and vitamin preparations containing the natural isomer of reduced folates
03/09/2010US7674487 Herbal composition for treating CD33+ acute and chronic myeloid leukemia and a method thereof
03/09/2010US7674485 Synergistic composition for the treatment of diabetes mellitus
03/09/2010US7674482 for producing acetylcholine and serotonin; improved cognitive function, induced and maintained sleep, reduced pain, inflammation, blood pressure, anxiety, asthma, duration of viral infection, insulin resistance, appetite, and treating depression
03/09/2010US7674480 Oral administering; Parkinson's dosease; hyperactivity; attention deficit disorder; using methylphenidate
03/09/2010US7674475 Mixture of moxidectin, praziquantel, benzyl alcohol, ethanol, colloidal silica, surfactants and oil; veterinary medicine
03/09/2010US7674463 Method of inhibiting angiogenesis by administration of a corticotropin releasing factor receptor 2 agonist
03/09/2010US7674457 treating neurodegenerative disorders by administering a human umbilical cord blood and mannitol blood brain barrier permeabilizer; biodrug treating cerebral ischemia; cells are selected from all different organs
03/09/2010US7674455 treating a mammal having amyotrophic lateral sclerosis by transducing a motor neuron of the mammal with an insulin-like growth factor I (IGF-1) gene or a glial cell line-derived neurotrophic factor (GDNF) gene; neurodegenerative disorders
03/09/2010US7674454 Enzyme-prodrug therapy for prosthetic joint repair
03/09/2010US7674453 Tumor necrosis factor combined with interferon in demyelinating diseases
03/09/2010CA2545968C Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
03/09/2010CA2543827C Selective androgen receptor modulators and methods of use thereof
03/09/2010CA2537598C Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
03/09/2010CA2493313C Novel benzodioxoles
03/09/2010CA2482346C Substituted phenylacetamides and their use as glucokinase activators
03/09/2010CA2472449C Pharmaceutical composition for oral use with improved absorption
03/09/2010CA2432279C Preparation of microparticles having improved flowability
03/09/2010CA2431952C Muscarinic antagonists
03/09/2010CA2424346C Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
03/09/2010CA2421819C Isoquinolinone potassium channel inhibitors
03/09/2010CA2420495C A novel cationic lipopolymer as biocompatible gene delivery agent